Free Trial
OTCMKTS:BGMD

BG Medicine (BGMD) Stock Price, News & Analysis

BG Medicine logo

About BG Medicine Stock (OTCMKTS:BGMD)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive BGMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BG Medicine and its competitors with MarketBeat's FREE daily newsletter.

BGMD Stock News Headlines

BG Medicine, Inc. (BGMD)
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Modernizing Medicine
Medicine Through Time
BGMD - BG Medicine, Inc.
Jiangsu Hengrui Medicine
See More Headlines

BGMD Stock Analysis - Frequently Asked Questions

BG Medicine, Inc. (OTCMKTS:BGMD) announced its quarterly earnings results on Tuesday, November, 17th. The medical research company reported ($0.27) EPS for the quarter. The medical research company had revenue of $334 million for the quarter, compared to the consensus estimate of $695 million.

Shares of BGMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BG Medicine investors own include Aeterna Zentaris (AEZS), Glu Mobile (GLUU), Blue Ridge Mountain Resources (MHRCQ), ARCA biopharma (ABIO), Athersys (ATHX), Bristol-Myers Squibb (BMY) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/17/2015
Today
5/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Life Sciences Tools & Services
Current Symbol
OTCMKTS:BGMD
Previous Symbol
NASDAQ:BGMD
Employees
5
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
2.03
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (OTCMKTS:BGMD) was last updated on 5/11/2025 by MarketBeat.com Staff
From Our Partners